FindTrial
Sign In

The effectiveness of temple stay in irritable bowel syndrome

Temple stay improves intestinal microbiome profile in patients with irritable bowel syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008588
Enrollment
100
Registered
2023-06-29
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Dongguk University Ilsan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 20-69 with diarrhea-predominant or constipation-predominant irritable bowel syndrome.

Exclusion criteria

Exclusion criteria: Monk, history of irritable bowel syndrome (constipation-predominant), history of inflammatory bowel disease, history of colorectal cancer, history of gastrointestinal resection, abnormal blood test (liver function test: AST or ALT more than 1.5 times the normal limit, total bilirubin increase of more than 1.5mg/dL, CCr < 30 mL/min, platelets less than 100,000, PT/aPTT increase of more than 20% of the normal upper limit), uncontrolled hypertension and diabetes.

Design outcomes

Primary

MeasureTime frame
Symptom score for IBS (IBS-SSS)—

Secondary

MeasureTime frame
Fecal gut microbiome—

Countries

Korea, Republic of

Contacts

Public ContactSang Hoon Kim

Dongguk University Ilsan Hospital

spring0107@naver.com+82-31-961-7128

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026